Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio observacional, prospectivo, multicéntrico y del mundo real para la HPN en China (ReWoPNH)

22 de septiembre de 2026 actualizado por: AstraZeneca

Un estudio observacional, prospectivo, multicéntrico y del mundo real sobre la hemoglobinuria paroxística nocturna (HPN) en China

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Tipo de estudio

De observación

Inscripción (Actual)

724

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Hangzhou, Porcelana
        • Research Site
    • Anhui
      • Hefei, Anhui, Porcelana, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100000
        • Research Site
      • Beijing, Beijing Municipality, Porcelana, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510080
        • Research Site
      • Guangzhou, Guangdong, Porcelana, 510180
        • Research Site
      • Guangzhou, Guangdong, Porcelana, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, Porcelana, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, Porcelana, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, Porcelana, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, Porcelana, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, Porcelana, 450003
        • Research Site
      • Zhengzhou, Henan, Porcelana, 450052
        • Research Site
      • Zhengzhou, Henan, Porcelana, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, Porcelana, 430030
        • Research Site
      • Wuhan, Hubei, Porcelana, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, Porcelana, 410008
        • Research Site
      • Changsha, Hunan, Porcelana, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210029
        • Research Site
      • Nantong, Jiangsu, Porcelana, 226001
        • Research Site
      • Xuzhou, Jiangsu, Porcelana, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 330006
        • Research Site
      • Nanchang, Jiangxi, Porcelana, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, Porcelana, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, Porcelana, 250000
        • Research Site
      • Qingdao, Shandong, Porcelana, 266000
        • Research Site
      • Zibo, Shandong, Porcelana, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, Porcelana, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, Porcelana, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, Porcelana, 030000
        • Research Site
      • Xi’an, Shanxi, Porcelana, 710061
        • Research Site
      • Xi’an, Shanxi, Porcelana, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610041
        • Research Site
      • Chengdu, Sichuan, Porcelana, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, Porcelana, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, Porcelana, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, Porcelana, 650034
        • Research Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Descripción

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Periodo de tiempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Periodo de tiempo: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Periodo de tiempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Periodo de tiempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Periodo de tiempo: 12 months

To characterize the progression of PNH

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number and percentage of patients with each symptom of interest within follow-up
Periodo de tiempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Periodo de tiempo: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Periodo de tiempo: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Periodo de tiempo: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Periodo de tiempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Periodo de tiempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Periodo de tiempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Periodo de tiempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Periodo de tiempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Periodo de tiempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Periodo de tiempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Periodo de tiempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Periodo de tiempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de noviembre de 2023

Finalización primaria (Actual)

3 de diciembre de 2025

Finalización del estudio (Actual)

3 de diciembre de 2025

Fechas de registro del estudio

Enviado por primera vez

30 de octubre de 2023

Primero enviado que cumplió con los criterios de control de calidad

23 de noviembre de 2023

Publicado por primera vez (Actual)

4 de diciembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • D7414R00001

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Marco de tiempo para compartir IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criterios de acceso compartido de IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir